# Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases

> **NCT01578668** · PHASE2 · COMPLETED · sponsor: **Guangzhou Medical University** · enrollment: 69 (actual)

## Conditions studied

- Lung Adenocarcinoma
- Brain Metastases

## Interventions

- **DRUG:** erlotinib
- **DRUG:** pemetrexed
- **DRUG:** cisplatin
- **DRUG:** erlotinib

## Key facts

- **NCT ID:** NCT01578668
- **Lead sponsor:** Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2015-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01578668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01578668, "Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01578668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*